The drug industry believes the data "paints a misleading picture" of what's actually going on with prescription drug prices, says Allyson Funk, spokeswoman for the trade group Pharmaceutical Research and Manufacturers of America. CMS' dashborad "focuses on a small subset of medicines and ignores the
Date: Nov 14, 2016
Category: Health
Source: Google
FairWarning: Drug lobbyists and campaign cash stymie bid to restrain Medicare prescription costs
In a written statement, however, PhRMA spokeswoman Allyson Funk said, There is significant price negotiation that already occurs within the Medicare prescription drug program. Pointing to the private companies that run the program, Funk added, Large, powerful purchasers negotiate discounts and re
Date: Nov 06, 2016
Category: Health
Source: Google
CMS proposal for prescription drug reimbursement called 'perverse' and 'dangerous' by one opponent
The Pharmaceutical Research and Manufacturers of America (PhRMA) spokesman Allyson Funk said the current Medicare Part B drug payment methodology is working as an effective, market-based pricing mechanism to control costs.
Date: Mar 10, 2016
Category: Health
Source: Google
Obama administration proposes new effort to combat high drug prices
Proposing sweeping changes to Medicare Part B drug reimbursement without thoughtful consideration and stakeholder input is not the right approach and puts Medicare patients who rely on these medicines at risk, Pharmaceutical Research and Manufacturers of America spokeswoman Allyson Funk said in a
Date: Mar 08, 2016
Category: Health
Source: Google
$3 Billion Worth of Cancer Drugs Thrown Away Per Year Due To Packaging, Study Finds
Allyson Funk, the senior director of the Pharmaceutical Research and Manufacturers of America (PhRMA), commented about the report findings, stating that changing the drugs' vial sizes is harder said than done.